Lincoln National Corp Incyte Corp Transaction History

Lincoln National Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 09, 2020	SELL	$85.07 - $109.69 $186,048 - $239,892	-2,187 Closed	0 $0
Q2 2020 Jul 31, 2020	BUY	$74.18 - $108.93 $162,231 - $238,229	2,187 New	2,187 $227,000
Q1 2020 Apr 24, 2020	SELL	$63.18 - $85.97 $229,532 - $312,329	-3,633 Closed	0 $0
Q4 2019 Feb 07, 2020	SELL	$73.04 - $95.72 $35,570 - $46,615	-487 Reduced 11.82%	3,633 $317,000
Q4 2018 Feb 08, 2019	BUY	$58.5 - $69.94 $241,020 - $288,152	4,120 New	4,120 $262,000
Q2 2018 Aug 08, 2018	SELL	$60.85 - $83.98 $189,547 - $261,597	-3,115 Closed	0 $0
Q1 2018 May 09, 2018	SELL	$83.06 - $100.98 $171,518 - $208,523	-2,065 Reduced 39.86%	3,115 $260,000
Q4 2017 Feb 13, 2018	BUY	$93.56 - $116.6 $250,740 - $312,488	2,680 Added 107.2%	5,180 $491,000
Q3 2017 Oct 31, 2017	SELL	$109.15 - $138.27 $17,136 - $21,708	-157 Reduced 5.91%	2,500 $292,000
Q2 2017 Aug 07, 2017	BUY	N/A	2,657	2,657 $335,000

657

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Lincoln National Corp, based on Form 13F filings with the SEC.

Stay updated on Lincoln National Corp with notifications on news.